{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:21:08Z","timestamp":1791991268063,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41575-024-00935-y","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T10:08:32Z","timestamp":1717409312000},"page":"572-584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn\u2019s disease in clinical practice"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-4825","authenticated-orcid":false,"given":"Dominik","family":"Bettenworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel G.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Bemelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"d\u2019Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"d\u2019Hoore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Feakins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaylyn","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruishen","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-6902","authenticated-orcid":false,"given":"Julian","family":"Panes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-9188","authenticated-orcid":false,"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rimola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-4454","authenticated-orcid":false,"given":"Siew C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-958X","authenticated-orcid":false,"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1893-7200","authenticated-orcid":false,"given":"Ilyssa O.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Bruining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Stenosis Therapy Anti-Fibrotic Research (STAR) Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"935_CR1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres, J., Mehandru, S., Colombel, J. F. & Peyrin-Biroulet, L. Crohn\u2019s disease. Lancet 389, 1741\u20131755 (2017).","journal-title":"Lancet"},{"key":"935_CR2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/gutjnl-2023-329963","volume":"73","author":"F Rieder","year":"2024","unstructured":"Rieder, F., Mukherjee, P. K., Massey, W. J., Wang, Y. & Fiocchi, C. Fibrosis in IBD: from pathogenesis to therapeutic targets. Gut 73, 854\u2013866 (2024).","journal-title":"Gut"},{"key":"935_CR3","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/0016-5085(85)90006-X","volume":"88","author":"RG Farmer","year":"1985","unstructured":"Farmer, R. G., Whelan, G. & Fazio, V. W. Long-term follow-up of patients with Crohn\u2019s disease. Relationship between the clinical pattern and prognosis. Gastroenterology 88, 1818\u20131825 (1985).","journal-title":"Gastroenterology"},{"key":"935_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1136\/gutjnl-2018-318081","volume":"68","author":"D Bettenworth","year":"2019","unstructured":"Bettenworth, D. et al. Assessment of Crohn\u2019s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. Gut 68, 1115\u20131126 (2019). This systematic review provides a comprehensive summary of currently used radiological approaches for detection and characterization of fibrostenosing Crohn\u2019s disease.","journal-title":"Gut"},{"key":"935_CR5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/apt.15750","volume":"51","author":"C Lu","year":"2020","unstructured":"Lu, C. et al. Systematic review: medical therapy for fibrostenosing Crohn\u2019s disease. Aliment. Pharmacol. Ther. 51, 1233\u20131246 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"935_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/ecco-jcc\/jjw055","volume":"10","author":"F Rieder","year":"2016","unstructured":"Rieder, F. et al. European Crohn\u2019s and Colitis Organisation topical review on prediction, diagnosis and management of fibrostenosing Crohn\u2019s disease. J. Crohns Colitis 10, 873\u2013885 (2016).","journal-title":"J. Crohns Colitis"},{"key":"935_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MIB.0000000000000988","volume":"23","author":"D Bettenworth","year":"2017","unstructured":"Bettenworth, D. et al. A pooled analysis of efficacy, safety, and long-term outcome of endoscopic balloon dilation therapy for patients with stricturing Crohn\u2019s disease. Inflamm. Bowel Dis. 23, 133\u2013142 (2017). Provides a multivariate analysis on efficacy and safety of endoscopic balloon dilation for fibrostenosing complications based on a large database with individual-level data from 676 patients with Crohn\u2019s disease.","journal-title":"Inflamm. Bowel Dis."},{"key":"935_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00535-016-1172-6","volume":"51","author":"D Bettenworth","year":"2016","unstructured":"Bettenworth, D., Lopez, R., Hindryckx, P., Levesque, B. G. & Rieder, F. Heterogeneity in endoscopic treatment of Crohn\u2019s disease-associated strictures: an international inflammatory bowel disease specialist survey. J. Gastroenterol. 51, 939\u2013948 (2016).","journal-title":"J. Gastroenterol."},{"key":"935_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson, N. C., Rieder, F. & Wynn, T. A. Fibrosis: from mechanisms to medicines. Nature 587, 555\u2013566 (2020).","journal-title":"Nature"},{"key":"935_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1755-1536-7-5","volume":"7","author":"D Bettenworth","year":"2014","unstructured":"Bettenworth, D. & Rieder, F. Medical therapy of stricturing Crohn\u2019s disease: what the gut can learn from other organs \u2013 a systematic review. Fibrogenes. Tissue Repair. 7, 5 (2014).","journal-title":"Fibrogenes. Tissue Repair."},{"key":"935_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1152\/physrev.00005.2021","volume":"102","author":"SN Lin","year":"2022","unstructured":"Lin, S. N. et al. Development of antifibrotic therapy for stricturing Crohn\u2019s disease: lessons from randomized trials in other fibrotic diseases. Physiol. Rev. 102, 605\u2013652 (2022).","journal-title":"Physiol. Rev."},{"key":"935_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.cgh.2021.05.054","volume":"20","author":"CA Steiner","year":"2022","unstructured":"Steiner, C. A. et al. Biomarkers for the prediction and diagnosis of fibrostenosing Crohn\u2019s disease: a systematic review. Clin. Gastroenterol. Hepatol. 20, 817\u2013846.e10 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"935_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1053\/j.gastro.2019.08.033","volume":"158","author":"IO Gordon","year":"2020","unstructured":"Gordon, I. O. et al. Histopathology scoring systems of stenosis associated with small bowel Crohn\u2019s disease: a systematic review. Gastroenterology 158, 137\u2013150.e1 (2020).","journal-title":"Gastroenterology"},{"key":"935_CR14","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1053\/j.gastro.2021.02.035","volume":"160","author":"C Ma","year":"2021","unstructured":"Ma, C. et al. An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials. Gastroenterology 160, 2291\u20132302 (2021).","journal-title":"Gastroenterology"},{"key":"935_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/gutjnl-2021-324374","volume":"71","author":"IO Gordon","year":"2022","unstructured":"Gordon, I. O. et al. International consensus to standardise histopathological scoring for small bowel strictures in Crohn\u2019s disease. Gut 71, 479\u2013486 (2022). Consensus statement on the appropriateness of histopathology scoring systems for fibrostenosing Crohn\u2019s disease.","journal-title":"Gut"},{"key":"935_CR16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/apt.16049","volume":"52","author":"D Bettenworth","year":"2020","unstructured":"Bettenworth, D. et al. Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn\u2019s disease strictures. Aliment. Pharmacol. Ther. 52, 1104\u20131116 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"935_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/apt.14853","volume":"48","author":"F Rieder","year":"2018","unstructured":"Rieder, F. et al. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn\u2019s disease. Aliment. Pharmacol. Ther. 48, 347\u2013357 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"935_CR18","doi-asserted-by":"publisher","first-page":"i418","DOI":"10.1093\/ecco-jcc\/jjac190.0400","volume":"17","author":"DB Bettenworth","year":"2023","unstructured":"Bettenworth, D. B. et al. A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn\u2019s disease. J. Crohns Colitis 17, i418\u2013i420 (2023).","journal-title":"J. Crohns Colitis"},{"key":"935_CR19","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/ajg.2017.166","volume":"112","author":"S Wani","year":"2017","unstructured":"Wani, S. et al. Development of quality indicators for endoscopic eradication therapies in Barrett\u2019s esophagus: the TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett\u2019s Esophagus) consortium. Am. J. Gastroenterol. 112, 1032\u20131048 (2017).","journal-title":"Am. J. Gastroenterol."},{"key":"935_CR20","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1136\/gutjnl-2020-322449","volume":"70","author":"R Hansen","year":"2021","unstructured":"Hansen, R. et al. Adaptations to the current ECCO\/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut 70, 1044\u20131052 (2021).","journal-title":"Gut"},{"key":"935_CR21","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1136\/gutjnl-2017-314341","volume":"67","author":"AYB Teoh","year":"2018","unstructured":"Teoh, A. Y. B. et al. Consensus guidelines on the optimal management in interventional EUS procedures: results from the Asian EUS group RAND\/UCLA expert panel. Gut 67, 1209\u20131228 (2018).","journal-title":"Gut"},{"key":"935_CR22","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1053\/j.gastro.2017.11.274","volume":"154","author":"DH Bruining","year":"2018","unstructured":"Bruining, D. H. et al. Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel Crohn\u2019s disease. Gastroenterology 154, 1172\u20131194 (2018).","journal-title":"Gastroenterology"},{"key":"935_CR23","unstructured":"Fitch, K. et al. The RAND\/UCLA Appropriateness Method User\u2019s Manual (RAND, 2001)."},{"key":"935_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.gastro.2016.09.047","volume":"152","author":"F Rieder","year":"2017","unstructured":"Rieder, F., Fiocchi, C. & Rogler, G. Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases. Gastroenterology 152, 340\u2013350.e6 (2017).","journal-title":"Gastroenterology"},{"key":"935_CR25","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/ibd\/izy050","volume":"24","author":"SL Hansel","year":"2018","unstructured":"Hansel, S. L. et al. Clinical benefit of capsule endoscopy in Crohn\u2019s disease: impact on patient management and prevalence of proximal small bowel involvement. Inflamm. Bowel Dis. 24, 1582\u20131588 (2018).","journal-title":"Inflamm. Bowel Dis."},{"key":"935_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2036.2011.04710.x","volume":"34","author":"J Panes","year":"2011","unstructured":"Panes, J. et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn\u2019s disease. Aliment. Pharmacol. Ther. 34, 125\u2013145 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"935_CR27","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1111\/j.1572-0241.2007.01537.x","volume":"102","author":"MV Chiorean","year":"2007","unstructured":"Chiorean, M. V. et al. Correlation of CT enteroclysis with surgical pathology in Crohn\u2019s disease. Am. J. Gastroenterol. 102, 2541\u20132550 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"935_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2036.2003.01673.x","volume":"18","author":"G Maconi","year":"2003","unstructured":"Maconi, G. et al. Small bowel stenosis in Crohn\u2019s disease: clinical, biochemical and ultrasonographic evaluation of histological features. Aliment. Pharmacol. Ther. 18, 749\u2013756 (2003).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"935_CR29","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1148\/radiol.2523082167","volume":"252","author":"S Punwani","year":"2009","unstructured":"Punwani, S. et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology 252, 712\u2013720 (2009).","journal-title":"Radiology"},{"key":"935_CR30","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N. Engl. J. Med. 362, 1383\u20131395 (2010).","journal-title":"N. Engl. J. Med."},{"key":"935_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11605-015-3061-3","volume":"20","author":"T Kono","year":"2016","unstructured":"Kono, T. et al. Kono-S anastomosis for surgical prophylaxis of anastomotic recurrence in Crohn\u2019s disease: an international multicenter study. J. Gastrointest. Surg. 20, 783\u2013790 (2016).","journal-title":"J. Gastrointest. Surg."},{"key":"935_CR32","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1148\/radiol.2513081184","volume":"251","author":"SS Lee","year":"2009","unstructured":"Lee, S. S. et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 251, 751\u2013761 (2009).","journal-title":"Radiology"},{"key":"935_CR33","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1053\/j.gastro.2019.03.051","volume":"157","author":"I Ordas","year":"2019","unstructured":"Ordas, I. et al. Development and validation of a simplified magnetic resonance index of activity for Crohn\u2019s disease. Gastroenterology 157, 432\u2013439.e1 (2019).","journal-title":"Gastroenterology"},{"key":"935_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5217\/ir.2018.00107","volume":"17","author":"Y Maehata","year":"2019","unstructured":"Maehata, Y. et al. Risk of surgery in patients with stricturing type of Crohn\u2019s disease at the initial diagnosis: a single center experience. Intest. Res. 17, 357\u2013364 (2019).","journal-title":"Intest. Res."},{"key":"935_CR35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1148\/radiol.2017171221","volume":"287","author":"XH Li","year":"2018","unstructured":"Li, X. H. et al. Characterization of degree of intestinal fibrosis in patients with Crohn disease by using magnetization transfer MR imaging. Radiology 287, 494\u2013503 (2018).","journal-title":"Radiology"},{"key":"935_CR36","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/ecco-jcc\/jjx186","volume":"12","author":"M Wagner","year":"2018","unstructured":"Wagner, M. et al. Magnetic resonance imaging predicts histopathological composition of ileal Crohn\u2019s disease. J. Crohns Colitis 12, 718\u2013729 (2018).","journal-title":"J. Crohns Colitis"},{"key":"935_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40477-017-0265-2","volume":"20","author":"C Serra","year":"2017","unstructured":"Serra, C. et al. Real-time elastography for the detection of fibrotic and inflammatory tissue in patients with stricturing Crohn\u2019s disease. J. Ultrasound 20, 273\u2013284 (2017).","journal-title":"J. Ultrasound"},{"key":"935_CR38","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ibd.21414","volume":"17","author":"M Zappa","year":"2011","unstructured":"Zappa, M. et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn\u2019s disease? A retrospective comparison with surgical pathologic analysis. Inflamm. Bowel Dis. 17, 984\u2013993 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"935_CR39","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/ibd.21801","volume":"18","author":"J Adler","year":"2012","unstructured":"Adler, J. et al. Computed tomography enterography findings correlate with tissue inflammation, not fibrosis in resected small bowel Crohn\u2019s disease. Inflamm. Bowel Dis. 18, 849\u2013856 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"935_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/gutjnl-2016-312581","volume":"67","author":"Y Bouhnik","year":"2018","unstructured":"Bouhnik, Y. et al. Efficacy of adalimumab in patients with Crohn\u2019s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut 67, 53\u201360 (2018). Multicentre, prospective, observational cohort study in patients with Crohn\u2019s disease with symptomatic small-bowel strictures demonstrating therapeutic efficacy of adalimumab.","journal-title":"Gut"},{"key":"935_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S2468-1253(21)00393-9","volume":"7","author":"JD Schulberg","year":"2022","unstructured":"Schulberg, J. D. et al. Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn\u2019s disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. Lancet Gastroenterol. Hepatol. 7, 318\u2013331 (2022). Open-label, RCT demonstrating that Crohn\u2019s disease strictures are responsive to drug treatment and that treat-to-target therapy intensification resulted in numerically fewer treatment failures and a reduction in stricture-associated inflammation.","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"935_CR42","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","volume":"15","author":"R Battat","year":"2017","unstructured":"Battat, R. et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s disease. Clin. Gastroenterol. Hepatol. 15, 1427\u20131434.e2 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"935_CR43","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","volume":"69","author":"X Roblin","year":"2020","unstructured":"Roblin, X. et al. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Gut 69, 1206\u20131212 (2020).","journal-title":"Gut"},{"key":"935_CR44","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.3390\/jcm11144202","volume":"11","author":"C Rubin de Celix","year":"2022","unstructured":"Rubin de Celix, C., Chaparro, M. & Gisbert, J. P. Real-world evidence of the effectiveness and safety of ustekinumab for the treatment of Crohn\u2019s disease: systematic review and meta-analysis of observational studies. J. Clin. Med. 11, 4202 (2022).","journal-title":"J. Clin. Med."},{"key":"935_CR45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2468-1253(19)30366-8","volume":"5","author":"B Shen","year":"2020","unstructured":"Shen, B. et al. Practical guidelines on endoscopic treatment for Crohn\u2019s disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol. Hepatol. 5, 393\u2013405 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"935_CR46","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/ecco-jcc\/jjw072","volume":"10","author":"NS Ding","year":"2016","unstructured":"Ding, N. S. et al. Endoscopic dilatation of Crohn\u2019s anastomotic strictures is effective in the long term, and escalation of medical therapy improves outcomes in the biologic era. J. Crohns Colitis 10, 1172\u20131178 (2016).","journal-title":"J. Crohns Colitis"},{"key":"935_CR47","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S2468-1253(17)30248-0","volume":"2","author":"CY Ponsioen","year":"2017","unstructured":"Ponsioen, C. Y. et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol. Hepatol. 2, 785\u2013792 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-00935-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-00935-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-00935-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T09:27:22Z","timestamp":1722245242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-00935-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["935"],"URL":"https:\/\/doi.org\/10.1038\/s41575-024-00935-y","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"19 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.B. is on the advisory board or consultant for AbbVie, Amgen, Arena, Atheneum, BNG Service GmbH, Bristol Myers Squibb, CED-Service GmbH, Celltrion, DGVS, Diaplan, Doctorflix, Else Kr\u00f6ner-Fresenius Foundation, Falk Foundation, Galapagos, Guidepoint, Impulze, Ferring, Janssen Cilag, Lilly, Medical Tribune, Med Today, MedTriX, MSD, Mylan, Onkowissen, Pharmacosmos, Pfizer, Roche, Sandoz, Takeda, Tetrameros, Thieme, Tillotts Pharma, UCB Biopharma, Viatris and Vifor Pharma. I.D. has served as a speaker, consultant and advisory board member for Takeda, Janssen, AbbVie, Pfizer, Ferring, Roche\/Genentech, Celgene\/BMS, Falk Pharma, Rafa Laboratories, Neopharm, Nestle, Arena, Gilead, MSD, DSM, Celltrion, Sublimity, Sandoz, Abbott and Athos Therapeutics. R.F. has served as central reader for Alimentiv, received speaker\u2019s fees from Janssen Pharmaceuticals and consulting fee from Decibio. M.E.B. receives no direct support. Cleveland Clinic receives support for him from Siemens Healthineers in the form of salary, software and hardware for the investigation of reduced exposure in CT enterography. S.A.T. is a research consultant to Robarts. J.P. received financial support for research from AbbVie and Pfizer; consultancy fees\/honorarium from AbbVie, Arena, Athos, Atomwise, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech\/Roche, GlaxoSmithKline, Janssen, Mirum, Morphic, Nestl\u00e9, Origo, Pandion, Pfizer, Progenity, Protagonist, Revolo, Robarts, Takeda, Theravance and Wasserman; reports payment for lectures including service on speaker\u2019s bureau from Abbott, Ferring, Janssen, Pfizer and Takeda; and reports payment for development of educational presentations from Abbott, Janssen, Pfizer, Roche and Takeda. J.R. is on the advisory board or consultant for Alimentiv, Boehringer Ingelheim, Janssen, Origo, Takeda and TiGenix; and received research grants from AbbVie and Genentech. W.B. served as speaker for Johnson & Johnson, Braun and Takeda; and obtained research grants from Braun, VIFOR and Medtronic. A.d\u2019H. has served as speaker for Johnson & Johnson and Takeda. A.D. has received research support or acted as a principal investigator for AbbVie, Arena, Dr. Falk Pharma, Celgene, Gilead, Janssen and Takeda; has acted as a consultant or AbbVie, Amgen, BMS, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Fresenius Kabi, Celltrion, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Roche, Takeda, Tillotts and Vifor; and has participated in speaker\u2019s bureaus for AbbVie, Amgen, Falk Foundation, Ferring, Janssen, Lilly, Med Today, Med Update, MSD, Pfizer, Roche, Streamed-up, Takeda, Tillotts and Vifor. W.J.S. reports consulting fees from Abbvie, Abivax, Alfasigma, Alimentiv, Beigene, Biora (Progenity), Celltrion, Forbion, Genentech, Gossamer Biosciences, Index Pharmaceuticals, Prometheus Biosciences, Protagonist Therapeutics, Shoreline Biosciences, Vedanta Biosciences, Ventyx Biosciences and Zealand Pharma; stock or stock options from BeiGene, Gossamer Bio, Biora (Progenity), Prometheus Biosciences, Prometheus Laboratories, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences; and is an employee at Shoreline Biosciences and Ventyx Biosciences (spouse: Iveric Bio (consultant, stock options); Biora (Progenity) (stock); Prometheus Biosciences (employee, stock, stock options); Prometheus Laboratories (stock, stock options); Ventyx Biosciences (stock, stock options); and Vimalan Biosciences (stock)). S.C.N. served as a speaker for AbbVie, Janssen, Tillotts, Menarini, Ferring, Takeda and Pfizer; and received research funding from Olympus, Janssen and Ferring. C.L. has received consulting fees from AbbVie, Janssen, Takeda, Fresenius Kabi, Ferring, Eli Lilly; speaker\u2019s fees from AbbVie, Janssen and Fresenius Kabi. D.H.B. is a consultant for Medtronics and Janssen; and receives research support from Medtronics and Takeda. G.R. is a consultant for Abbott, AbbVie, Augurix, Boehringer, Calypso, FALK, Ferring, Fisher, Genentech, Essex\/MSD, Novartis, Pfizer, Phadia, Roche, Takeda, Tillots, UCB, Vifor, Vital Solutions and Zeller; received speaker\u2019s honoraria from AstraZeneca, Abbott, AbbVie, FALK, MSD, Phadia, Tillots, UCB and Vifor; and received educational grants and research grants from Abbot, AbbVie, Ardeypharm, Augurix, Calypso, Essex\/MSD, FALK, Flamentera, Novartis, Roche, Takeda, Tillots, UCB and Zeller. B.V. Received research support from AbbVie, Biora Therapeutics, Pfizer, Sossei Heptares and Takeda; speaker\u2019s fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and consultancy fees from Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris. G.d\u2019H. reports consultancy activities for AbbVie, Agomab, Alimentiv, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, GlaxoSmithKline, Gossamerbio, Pfizer, Immunic, Johnson & Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenit and Protagonist; speaker\u2019s bureau for AbbVie, Arena, Galapagos, Gilead, Pfizer, BMS and Takeda; and fees for data monitoring board activities for Galapagos, AbbVie, AstraZeneca and Seres Health. B.S. has served as consultant for Abbvie, Arena, BMS, Boehringer, Celgene, Falk, Galapagos, Gilead, Janssen, Lilly, Pfizer, PredictImmune, Prometheus and Takeda; and received speaker\u2019s fees from Abbvie, CED Service GmbH, Falk, Ferring, Galapagos, Janssen, Lilly, Novartis, Pfizer and Takeda (served as representative of the Charit\u00e9). P.F. is consultant to Takeda. C.H. has served as a consultant or on advisory boards of AbbVie, Genentech, Janssen, Pfizer, Samsung Bioepis and Takeda. I.O.G. receives no direct support; Cleveland Clinic receives support for her from UCB, Celgene and Pliant Therapeutics. J.G.F. receives grants to his institution from Siemens Healthineers and Medtronic. V.J. receives salary support from the John and Susan McDonald Endowed IBD Chair at Western University, London, Ontario, Canada; consulting fees from AbbVie, Eli Lilly, GlaxoSmithKline, Arena Pharmaceuticals, Genentech, Pendopharm, Sandoz, Merck, Takeda, Janssen, Robarts Clinical Trials, Topivert and Celltrion; speaker\u2019s fees from Takeda, Janssen, Shire, Ferring, Abbvie and Pfizer. B.G.F. has received grant and research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma AG, AbbVie, Novartis Pharmaceuticals, Centocor Inc., Elan\/Biogen, UCB Pharma, Bristol-Myers Squibb, Genentech, ActoGenix and Wyeth Pharmaceuticals Inc.; consulting fees from Millennium Pharmaceuticals, Merck, Centocor Inc., Elan\/Biogen, Janssen-Ortho, Teva Pharmaceuticals, Bristol-Myers Squibb, Celgene, UCB Pharma, AbbVie, AstraZeneca, Serono, Genentech, Tillotts Pharma AG, Unity Pharmaceuticals, Albireo Pharma, Given Imaging Inc., Salix Pharmaceuticals, Novo Nordisk, GSK, Actogenix, Prometheus Therapeutics and Diagnostics, Athersys, Axcan, Gilead, Pfizer, Shire, Wyeth, Zealand Pharma, Zyngenia, GiCare Pharma Inc. and Sigmoid Pharma; and speaker\u2019s bureau fees from UCB, AbbVie and J&J\/Janssen. F.R. is consultant to Adnovate, Agomab, Allergan, AbbVie, Arena, Boehringer-Ingelheim, Celgene\/BMS, CDISC, Celsius, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Mopac, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios and 89Bio. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}